Akron Children's > For Families & Patients > Research > Pediatric Clinical Studies > Open Clinical Studies
Safety and Efficacy of REN001 in patients with Primary Mitochondrial Myopathy
Full IRB Study Title:
A double-blind, placebo-controlled study to evaluate the efficacy and safety of 24 weeks treatment with RNE001 in patients with primary mitochondrial myopathy
IRB Study ID: 1737950
Please view complete study details here.
Study Sponsor:
Reneo Pharma Ltd
We are currently recruiting
If you are interested in this study or have questions about your child's eligibility, please contact:
Hilary Tonni; htonni@akronchildrens.org; 220-543-4734
Lead Investigator
Bruce H. Cohen, MD, FAAN
Chair, NeuroDevelopmental Science Center; Philip H. Maynard Chair in NeuroDevelopmental Science Fund; Chairman, American Academy of Neurology Advocacy Committee; Pediatric Neurologist
Pediatric Brain Tumor ProgramPediatric NeurologyMitochondrial Center
